Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hodgkin Disease × Salvage Therapy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 3 Recurrence 1 Rectal Neoplasms 1 Neuroendocrine Tumors 1 Melanoma 1 Lymphoma, T-Cell, Peripheral 1 Leukemia, Myeloid, Acute 1 Leukemia, Erythroblastic, Acute 1 Hodgkin Disease 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

Cyclophosphamide 179 fludarabine phosphate 107 Etoposide 100 Peripheral Blood Stem Cell Transplantation 91 Filgrastim 83 Mycophenolic Acid 81 Doxorubicin 78 Whole-Body Irradiation 74 Melphalan 73 Brentuximab Vedotin 70 Radiotherapy 69 Tacrolimus 67 fludarabine 64 Busulfan 64 Vinblastine 59 Cyclosporine 58 Rituximab 56 Dacarbazine 49 Gemcitabine 48 Granulocyte Colony-Stimulating Factor 47 Bleomycin 47 Vincristine 43 Antilymphocyte Serum 43 Prednisone 41 Cytarabine 41 Nivolumab 40 Methotrexate 39 Carmustine 34 pembrolizumab 31 Sirolimus 27

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04378647 2024-02-26

BRESELIBET

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2 Recruiting

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡